open access: Evaluation of Genomic Applications in Practice and Prevention (EGAPP) (breast, ovarian, Lynch Syndrome...)

Evaluation of Genomic Applications in Practice and Prevention (EGAPP): Implementation and Evaluation of a Model Approach

The EGAPP initiative was launched by the CDC Office of Public Health Genomics in the fall of 2004. The initiative's goal is to establish and evaluate a systematic, evidence-based process for assessing genetic tests and other applications of genomic technology in transition from research to clinical and public health practice. EGAPP also aims to integrate:

• existing recommendations on implementation of genetic tests from professional organizations and advisory committees.^1,2,3,4
• knowledge and experience gained from existing processes for evaluation and appraisal (e.g., US Preventive Services Task Force, CDC’s Task Force on Community Preventive Services), previous CDC initiatives (e.g., the ACCE process for assembling and analyzing data on genetic tests; http://www.cdc.gov/genomics/gtesting/ACCE/FBR/index.htm) 5, and the international health technology assessment experience.

............................................................................

Working Group: Topics

Completed Topics | Topics Under Review | Topics Identified

The Cancer Genome Atlas completes detailed ovarian cancer analysis - GenOmics

also: A more detailed press release on the study will be available from the National Institutes of Health at http://nih.gov/news/.

Genomic Health Says Gene Test Alters Breast Cancer Therapy - Businessweek (21 gene test)

website TCGA Cancer Genomics + 20 cancer study (including ovarian) updated Jan 2011

About Cancer Genomics

Explore information and resources to improve your understanding
of cancer genomics, the importance of tumor samples in genomic
research and the role of cancer genomics in personalized medicine.

plus:

Cancers Selected for Study

Following the success of The Cancer Genome Atlas (TCGA)
Pilot Project, NIH announced in September 2009 that it is
investing $275 million in TCGA over the next two years of
this five-year program to chart the genomic changes
involved in more than 20 types of cancer. To date,
TCGA has achieved comprehensive sequencing,
characterization, and analysis of the genomic changes
in the brain cancer, glioblastoma multiforme, and
ovarian cancer.

CANCER TISSUES BEING COLLECTED FOR POTENTIAL STUDY

Last Updated: January 16, 2011 Expand All | Collapse All

Central Nervous System (Brain)

Cancer Type	Sample Collection Complete	Data Publicly Available
Glioblastoma Multiforme

Breast

Cancer Type	Sample Collection Complete	Data Publicly Available
Breast Lobular Carcinoma
Breast Ductal Carcinoma

Gastrointestinal

Cancer Type	Sample Collection Complete	Data Publicly Available
Colon Adenocarcinoma
Rectal Adenocarcinoma
Stomach Adenocarcinoma

Gynecologic

Cancer Type	Sample Collection Complete	Data Publicly Available
Ovarian Serous Cystadenocarcinoma
Uterine Corpus Endometrial Carcinoma

Head and Neck

Cancer Type	Sample Collection Complete	Data Publicly Available
Head and Neck Squamous Cell Carcinoma
Thyroid Carcinoma

Hematologic

Cancer Type	Sample Collection Complete	Data Publicly Available
Acute Myeloid Leukemia

Thoracic

Cancer Type	Sample Collection Complete	Data Publicly Available
Lung Adenocarcinoma
Lung Squamous Cell Carcinoma

Urologic